3,4-dihydroxyphenylacetic acid and quinone

3,4-dihydroxyphenylacetic acid has been researched along with quinone in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (83.33)29.6817
2010's1 (16.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J1
Cadenas, E; Laranjinha, J1
Cho, Y; Choi, HJ; Hwang, O; Lee, SY1
Asanuma, M; Diaz-Corrales, FJ; Miyazaki, I; Ogawa, N; Shimizu, M; Tanaka, K1
Bagh, MB; Banerjee, K; Chakrabarti, S; Das, A; Jana, S; Maiti, AK; Roy, A1
Anderson, DG; Buettner, GR; Doorn, JA; Mariappan, SV1

Other Studies

6 other study(ies) available for 3,4-dihydroxyphenylacetic acid and quinone

ArticleYear
Chemical genetics reveals a complex functional ground state of neural stem cells.
    Nature chemical biology, 2007, Volume: 3, Issue:5

    Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells

2007
Oxidation of DOPAC by nitric oxide: effect of superoxide dismutase.
    Journal of neurochemistry, 2002, Volume: 81, Issue:4

    Topics: 3,4-Dihydroxyphenylacetic Acid; Ascorbic Acid; Benzoquinones; Electron Spin Resonance Spectroscopy; Glutathione; Models, Biological; Nitric Oxide; Oxidation-Reduction; Peroxynitrous Acid; Superoxide Dismutase

2002
Inhibition of vesicular monoamine transporter enhances vulnerability of dopaminergic cells: relevance to Parkinson's disease.
    Neurochemistry international, 2005, Volume: 46, Issue:4

    Topics: 3,4-Dihydroxyphenylacetic Acid; Acetylcysteine; Animals; Benzoquinones; Biopterins; Cell Death; Cell Line; Cytosol; Dimethyl Fumarate; Dopamine; Drug Resistance; Enzyme Inhibitors; Fumarates; Ketanserin; Lipid Peroxidation; Membrane Glycoproteins; Membrane Transport Modulators; Membrane Transport Proteins; Mice; Monoamine Oxidase Inhibitors; Neurons; Oxidative Stress; Parkinson Disease; Substantia Nigra; Vesicular Biogenic Amine Transport Proteins; Vesicular Monoamine Transport Proteins

2005
Pramipexole has ameliorating effects on levodopa-induced abnormal dopamine turnover in parkinsonian striatum and quenching effects on dopamine-semiquinone generated in vitro.
    Neurological research, 2005, Volume: 27, Issue:5

    Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Antiparkinson Agents; Benzoquinones; Benzothiazoles; Corpus Striatum; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Drug Interactions; Electron Spin Resonance Spectroscopy; Functional Laterality; Homovanillic Acid; Levodopa; Male; Mice; Mice, Inbred ICR; Oxidopamine; Parkinson Disease; Pramipexole; Thiazoles; Time Factors

2005
Dopamine but not 3,4-dihydroxy phenylacetic acid (DOPAC) inhibits brain respiratory chain activity by autoxidation and mitochondria catalyzed oxidation to quinone products: implications in Parkinson's disease.
    Brain research, 2007, Mar-30, Volume: 1139

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Benzoquinones; Brain; Dopamine; Electron Transport; Electron Transport Chain Complex Proteins; Mitochondria; Oxidation-Reduction; Parkinson Disease; Rats; Rats, Inbred Strains

2007
Oxidation of 3,4-dihydroxyphenylacetaldehyde, a toxic dopaminergic metabolite, to a semiquinone radical and an ortho-quinone.
    The Journal of biological chemistry, 2011, Jul-29, Volume: 286, Issue:30

    Topics: 3,4-Dihydroxyphenylacetic Acid; Benzoquinones; Cyclooxygenase 2; Free Radicals; Humans; Oxidation-Reduction; Parkinson Disease

2011